According to a research report published earlier today, Piper Jaffray has initiated Athersys Inc. ATHX with an Overweight rating and $4 PT.
Piper Jaffray explained in the report, “Athersys is a regenerative medicine company developing MultiStem, an offthe-shelf stem cell therapy comprised of multipotent adult progenitor cells (MAPCs). Athersys is scheduled to discuss the design of a pivotal study in graft-vs. host disease (GvHD) with the FDA in May, offering a potential fast path to market. Athersys also partnered MultiStem with Pfizer in inflammatory bowel disease (IBD) with data from a randomized Phase II study expected in 1Q:13. Beyond these indications, Athersys is developing MultiStem for stroke and heart attack. Athersys recently raised $9 million in a private placement bringing pro forma cash to ~$25 million, which should last into mid'13. Trading at an enterprise value of only $22 million, we view Athersys as an attractive regenerative medicine play with multiple shots on goal.”
Athersys closed yesterday at $1.67.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in